Atlas Trials

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Clinical trial NCT00849667 · TERMINATED

Trial details

NCT number
NCT00849667
Sponsor
Morphotek
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2009-04-16
Primary completion
2012-12-31
Enrollment
1100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.